Humana (HUM) Upgraded at Jefferies Group
Jefferies Group upgraded shares of Humana (NYSE:HUM) from a hold rating to a buy rating in a research note issued to investors on Friday, Marketbeat Ratings reports. Jefferies Group currently has $221.00 target price on the insurance provider’s stock.
Several other analysts have also commented on the company. Goldman Sachs Group initiated coverage on Humana in a report on Wednesday, January 3rd. They set a buy rating and a $305.00 target price on the stock. ValuEngine lowered Humana from a buy rating to a hold rating in a report on Tuesday, December 19th. Cowen reissued a buy rating and issued a $285.00 price objective on shares of Humana in a report on Wednesday, December 13th. Cantor Fitzgerald reissued a hold rating and issued a $230.00 price objective on shares of Humana in a report on Tuesday, December 5th. Finally, Credit Suisse Group dropped their price objective on Humana from $256.00 to $246.00 and set a neutral rating on the stock in a report on Friday, November 10th. Nine investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $260.10.
Shares of Humana (HUM) opened at $268.02 on Friday. The company has a market capitalization of $38,289.36, a PE ratio of 21.09, a P/E/G ratio of 1.70 and a beta of 0.88. Humana has a 1-year low of $186.25 and a 1-year high of $271.99. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35.
Humana (NYSE:HUM) last posted its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping the consensus estimate of $3.27 by $0.12. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. Humana’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period last year, the company earned $3.18 earnings per share. analysts predict that Humana will post 11.63 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.60%. Humana’s dividend payout ratio (DPR) is presently 12.59%.
Humana declared that its board has authorized a stock repurchase plan on Thursday, December 14th that permits the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization permits the insurance provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.
In other news, SVP Jody L. Bilney sold 7,054 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the transaction, the senior vice president now owns 11,704 shares in the company, valued at $2,901,304.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the completion of the transaction, the vice president now owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,115 shares of company stock worth $2,501,627. Company insiders own 0.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Los Angeles Capital Management & Equity Research Inc. lifted its position in shares of Humana by 228.4% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,691 shares of the insurance provider’s stock valued at $888,000 after acquiring an additional 2,567 shares in the last quarter. Schroder Investment Management Group lifted its position in shares of Humana by 70.8% in the second quarter. Schroder Investment Management Group now owns 58,792 shares of the insurance provider’s stock valued at $14,071,000 after acquiring an additional 24,367 shares in the last quarter. AXA lifted its position in shares of Humana by 4.5% in the second quarter. AXA now owns 28,100 shares of the insurance provider’s stock valued at $6,761,000 after acquiring an additional 1,200 shares in the last quarter. Martingale Asset Management L P purchased a new position in Humana during the second quarter worth approximately $482,000. Finally, Northwestern Mutual Wealth Management Co. lifted its position in Humana by 139.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock worth $134,000 after buying an additional 325 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.